First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19
Wednesday, May 6, 2020 7:00 AM
First Phase III Pivotal Study for an anti-GM-CSF Therapy in COVID-19 Patients
- First US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product approval for COVID-19
- Targeting prevention of serious outcomes in adult, hospitalized patients with COVID-19 pneumonia